David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Enco + Bini vs. Dab + Tram in BRAFV600E NSCLC 1L?
New indirect data suggests Enco + Bini may lead in both PFS and safety. However, cross-trial comparisons have limits!
Eyes on the upcoming IFCT lung ONCOBRAF phase 2 Trial update for more definitive insights.”
More posts featuring David Planchard
